Publications (7)23.75 Total impact
-
Article: Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to assess the expression levels for TβRI, TβRII, and TβRIII in epithelial layers of oral premalignant lesions (oral leukoplakia, OLK) and oral squamous cell carcinoma (OSCC), as well as in oral carcinoma-associated fibroblasts (CAFs), with the final goal of exploring the roles of various types of TβRs in carcinogenesis of oral mucosa. Normal oral tissues, OLK, and OSCC were obtained from 138 previously untreated patients. Seven primary human oral CAF lines and six primary normal fibroblast (NF) lines were established successfully via cell culture. The three receptors were detected using immunohistochemical (IHC), quantitative RT-PCR, and Western blot approaches. IHC signals for TβRII and TβRIII in the epithelial layer decreased in tissue samples with increasing disease aggressiveness (P < 0.05); no expression differences were observed for TβRI, in OLK and OSCC (P > 0.05); and TβRII and TβRIII were significantly downregulated in CAFs compared with NFs, at the mRNA and protein levels (P < 0.05). Exogenous expression of TGF-β1 led to a remarkable decrease in the expression of TβRII and TβRIII in CAFs (P < 0.05). This study provides the first evidence that the loss of TβRII and TβRIII expression in oral epithelium and stroma is a common event in OSCC. The restoration of the expression of TβRII and TβRIII in oral cancerous tissues may represent a novel strategy for the treatment of oral carcinoma.BMC Cancer 02/2011; 11:88. · 3.01 Impact Factor -
Article: Carcinoma-associated fibroblasts promotes the proliferation of a lingual carcinoma cell line by secreting keratinocyte growth factor.
[show abstract] [hide abstract]
ABSTRACT: Carcinoma-associated fibroblasts (CAFs) have been confirmed to play an important role in the occurrence and development of many kinds of tumors. Regarding proliferation as one manifestation of malignance, the objective was to observe the effects of oral CAFs on the proliferation of oral squamous carcinoma cells (OSCC) and to explore the role of keratinocyte growth factor (KGF) in this process. The results showed that oral CAFs secreted a higher level of KGF than oral normal fibroblasts (NFs), and the conditioned medium of CAFs could increase the viability of carcinoma cells and promote more of them into G2 and S phase. However, after blocking with KGF antibody, the viability and cell cycle of Tca8113 cultured with CAFs conditioned medium changed to be similar with NFs control groups. It was concluded that CAFs could promote the proliferation of OSCC through secreting high levels of KGF. These findings support the use of carcinoma-associated fibroblasts as a novel target in anticancer therapy.Tumor Biology 02/2011; 32(3):597-602. · 1.94 Impact Factor -
Article: Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP.
[show abstract] [hide abstract]
ABSTRACT: Bone marrow transplantation can provide an effective cell-based strategy to enhance bone repair. However, the fate of implanted cells and the extent of their contribution to bone osteoinduction remain uncertain. To define the fate of bone marrow-derived cells and their contribution in vivo, we used a bone-specific collagen I promoter (2.3Col) driving green fluorescent protein (GFP) (2.3ColGFP) within a lentiviral vector. Prior to in vivo cell fate determination, we verified a high efficiency of lentiviral transduction in human bone marrow stromal cells (hBMSCs), without altering the proliferation or differentiation potential of these cells. We showed that the 2.3ColGFP marker responded to endogenous transcriptional regulation signals. In a mouse ossicle model, we demonstrated that the 2.3ColGFP marker is able to specifically define human bone marrow-derived stem cells that enter the osteoblast lineage in vivo. In addition, cells labeled with 2.3ColGFP with the donor origin, directly make a major contribution to bone formation. Furthermore, we also demonstrated in a calvarial defect model that a mixture of human bone marrow-derived populations, have stronger bone regenerative potential than that of hBMSCs, and an optimal dose is required for bone regeneration by the mixed populations.Molecular Therapy 08/2009; 17(11):1967-78. · 6.87 Impact Factor -
Article: Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.
[show abstract] [hide abstract]
ABSTRACT: Therapeutic radiation is commonly used in the treatment of squamous cell carcinoma of the oral cavity and pharynx. Despite the proven efficacy of this form of anticancer therapy, high-dose radiation treatment is invariably associated with numerous unwanted side effects. This is particularly true for bone, in which radiation treatment often leads to osteoradionecrosis. The aim of this study was to investigate if treatment with arsenic trioxide (As(2)O(3)) could enhance the antitumor effect of radiotherapy whereas minimizing the destructive effects of radiation on bone. As(2)O(3) treatment induced a dose-dependent (1-20 mumol/L) inhibition of endothelial and tumor cell (OSCC-3 and UM-SCC-74A) survival and significantly enhanced radiation-induced endothelial cell and tumor cell death. In contrast, As(2)O(3) treatment (0.5-7.5 mumol/L) induced the proliferation of osteoblasts and also protected osteoblasts against radiation-induced cell death. Furthermore, As(2)O(3) treatment was able to significantly enhance radiation-induced inhibition of endothelial cell tube formation and tumor cell colony formation. To test the effectiveness of As(2)O(3) and radiation treatment in vivo, we used a severe combined immunodeficiency mouse model that has a bone ossicle and tumor growing side by side subcutaneously. Animals treated with As(2)O(3) and radiation showed a significant inhibition of tumor growth, tumor angiogenesis, and tumor metastasis to the lungs as compared with As(2)O(3) treatment or radiation treatment alone. In contrast, As(2)O(3) treatment protected bone ossicles from radiation-induced bone loss. These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation.Molecular Cancer Therapeutics 07/2008; 7(7):2060-9. · 5.23 Impact Factor -
Article: Pingyangmycin loaded bovine serum albumin microspheres for chemoembolization therapy--in vitro and in vivo studies.
[show abstract] [hide abstract]
ABSTRACT: Chemoembolization based on microspheres have been emerged as a novel and promising way for interventional therapy, however, the exact effect and probable mechanism have not been revealed. The purpose of our study was to evaluate the potential of Pingyangmycin loaded bovine serum albumin microspheres (PYM-BSA-MSs) for chemoembolization therapy both in vitro and in vivo. The effect of PYM-BSA-MSs on cell growth curves and changes of cell morphology and activities measured by MTT assay were carried out in human umbilical vein endothelial ECV-304 cells. The in vivo occlusion effect was evaluated in 24 healthy rabbits. Macroscopic examinations and Hematoxylin-Eosin (H-E) staining of cross-section of rabbits' central auricular arteries were employed to observe the apparent and histological changes of arterioles. The results show that the PYM-BSA-MSs could inhibit the proliferation and induce the apoptosis of ECV-304 cells in a time-dependent manner. In vivo studies demonstrated that 21 days after artery embolization with the PYM-BSA-MSs, neointimal thickening of arterioles and significant hyperplasia of endothelial cells could be detected, but without completely interruption of blood flow. Compared with plain PYM aqueous solution or BSA-MSs oily suspension, PYM-BSA-MSs showed excellent potential as an alternative to interventional embolization materials.International Journal of Pharmaceutics 04/2008; 351(1-2):219-26. · 3.35 Impact Factor -
Article: Preparation and characterization of Pingyangmycin-loaded bovine serum albumin microspheres for embolization therapy.
[show abstract] [hide abstract]
ABSTRACT: Bovine serum albumin microspheres (BSA-MSs) containing Pingyangmycin hydrochloride (PYM) were prepared for the interventional embolization by an emulsification-crosslinking method. The average diameter of the MSs was 83.6 microm with 80% ranging from 35 to 200 microm. The MSs showed a rather high entrapment efficiency (EE%) of 87.6+/-5.7% and the drug loading efficacy (DL%) was 20.2+/-1.3%. The drug release behaviors were evaluated both in vitro and in vivo, using UV-spectroscopy and HPLC, respectively. The in vitro results showed a significantly delayed release of drug for 10 days. The central auricular artery of rabbit was chosen as an embolization sites to study the in vivo drug release and the pharmacokinetics of the MSs compared with PYM injections. Experiments performed by artery perfusion and embolization in rabbits central auricular artery revealed that the PYM loaded BSA-MSs (PYM-BSA-MSs) could obviously prolong in vivo drug release, extend the mean residence time (MRT) and had equal bioavailability compared with plain PYM injections. These results demonstrated that by embolization of the central auricular artery with PYM-BSA-MSs, the local drug concentration could maintain at a relative high level for a longer time, thus achieve the aim of tumor targeting therapy. PYM-BSA-MSs are excellent potential alternatives of interventional embolization materials for the treatment of maxillofacial region tumors.International Journal of Pharmaceutics 06/2007; 336(2):361-6. · 3.35 Impact Factor -
Article: [A study of effects of pingyangmycin injection on treatment of lymphangiomas in oral, maxillofacial and cervical regions].
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to investigate the indication and therapeutic effects of Pingyangmycin injection as a primary therapy of lymphangiomas in oral, maxillofacial and cervical region. A total of 195 patients (106 males and 89 females) with lymphangiomas in oral and maxillofacial regions were treated in the affiliated dental hospital of Sichuan University from May 1990 to December 2000. The patients' ages ranged from 0.5 to 46 years. The tongue was the most commonly involved site, followed by the cheek and the neck. The 200 lymphangiomas (5 patients had 2 lymphangiomas in different sites) underwent the therapy of Pingyangmycin, which was injected as with 1 mg/ml in saline. The total dose of Pingyangmycin ranged from 5 mg to 70 mg and 5 to 58 times, 1 time per 2-4 weeks. The curative rate of cystic-type lymphangiomas was the highest. Of the 51 cystic lymphangiomas, 110 capillary lymphangiomas, 18 cavernous lymphangiomas and 21 combinations of capillary and cavenous lymphangiomas, the curative rates were respectively 100% (51), 46.36% (51), 16.16% (3) and 19.05% (4), which showed a significant therapeutic effect, respectively. And 40(78.43%), 19(17.27%), 2(11.11%) and 0(0%) of them completely disappeared. There was no serious side effect with Pingyangmycin-injection treatment, such as pulmonary fibrosis. The treatment of injection of Pingyangmycin is a selective primary method of lymphangiomas, which can reduce the size of lymphangiomas, and make them completely disappeared.Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology 07/2002; 20(3):184-6.
Top co-authors
Top Journals
Institutions
-
2002–2009
-
Sichuan University
Chengdu, Sichuan Sheng, China
-
